Sanofi reported stronger than expected third-quarter profit on Friday, boosted by demand for blockbuster asthma drug Dupixent ...
Sanofi (SNY) stock gains as the company posts a Q3 beat for 2025, driven mainly by Dupixent, an asthma therapy it markets ...
Sanofi India Limited (SIL) announced that its board of directors, on the recommendation of the Nomination and Remuneration ...
The MoU supports Saudi Vision 2030 and the National Transformation Program’s focus on localizing healthcare manufacturing ...
Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient careNEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ...
Sanofi posted strong Q3 results amid currency challenges; discover key pipeline updates and growth prospects for investors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback